Literature DB >> 23851633

Compounding bevacizumab for intravitreal injection: does USP <797> always apply?

Gary Shienbaum1, Harry W Flynn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851633     DOI: 10.1097/IAE.0b013e31829f742c

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  3 in total

1.  Sustained Anti-Vascular Endothelial Growth Factor Activity of Aflibercept (Eylea) After Storage in Polycarbonate Syringes Used for Intravitreal Injection: A Pathway to Safety and Efficiency.

Authors:  Dennis P Han; Christine Skumatz; Joseph C Besharse; Iris S Kassem
Journal:  J Ocul Pharmacol Ther       Date:  2019-03-27       Impact factor: 2.671

2.  Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Curr Ophthalmol Rep       Date:  2014-03-01

Review 3.  Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment.

Authors:  Nidhi Relhan; Thomas A Albini; Avinash Pathengay; Ajay E Kuriyan; Darlene Miller; Harry W Flynn
Journal:  Br J Ophthalmol       Date:  2015-12-23       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.